 |
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Firm,” 6990.HK) right this moment introduced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also referred to as SKB264/MK-2870) (佳泰莱®) together with MSD’s anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[1]) was granted Breakthrough Remedy Designation (BTD) by the Middle for Drug Analysis (CDE) of the Nationwide Medical Merchandise Administration (NMPA) of China for the first-line remedy of sufferers with regionally superior or metastatic non-small cell lung most cancers (NSCLC) who’ve PD-L1 tumor proportion rating (TPS)≥1% and are EGFR-negative and ALK-negative.
BTD is granted for remedy regimens that present efficient remedy or prevention for situations with no at present obtainable remedy, or that display vital medical benefits over at present obtainable remedies. For medication included within the breakthrough remedy course of, if related situations are met, purposes for conditional approval and precedence evaluation and approval could be submitted when making use of for advertising and marketing authorization.
Beforehand, the corporate introduced that outcomes from the Section III medical trial of OptiTROP-Lung05, evaluating sac-TMT together with pembrolizumab as first-line remedy for PD-L1-positive NSCLC, demonstrated a statistically vital and clinically significant enchancment in its main endpoint of progression-free survival (PFS). A optimistic development was additionally noticed in general survival (OS). OptiTROP-Lung05 is the primary Section III examine of an immunotherapy and ADC mixture to satisfy its main endpoint within the first-line remedy of NSCLC. Granting of BTD for the first-line remedy of PD-L1-positive NSCLC indication presents pathways to expedite the evaluation and potential approval technique of sac-TMT for this indication.
To this point, sac-TMT has acquired 5 BTDs for:
- regionally superior or metastatic triple-negative breast most cancers (TNBC) in July 2022;
- regionally superior or metastatic EGFR-mutant NSCLC after development on EGFR-TKI remedy in January 2023;
- regionally superior or metastatic hormone-receptor optimistic (HR+) and human epidermal progress issue receptor 2-negative (HER2-) breast most cancers (BC) in sufferers who’ve beforehand acquired at the least two strains of systemic chemotherapy in June 2023;
- first-line remedy of unresectable regionally superior, recurrent or metastatic PD-L1 damaging TNBC in March 2024;
- Together with anti-PD-L1 monoclonal antibody tagitanlimab for the first-line remedy of regionally superior or metastatic non-squamous NSCLC with out actionable genomic alterations in June 2025.
About sac-TMT
Sac-TMT, a core product of the Firm, is a novel human TROP2 ADC during which the Firm has proprietary mental property rights, concentrating on superior strong tumors akin to NSCLC, BC, gastric most cancers (GC), gynecological tumors, amongst others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of seven.4. Sac-TMT particularly acknowledges TROP2 on the floor of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA harm to tumor cells, which in flip results in cell-cycle arrest and apoptosis. As well as, it additionally releases KL610023 within the tumor microenvironment. Provided that KL610023 is membrane permeable, it may allow a bystander impact, or in different phrases kill adjoining tumor cells.
In Might 2022, the Firm licensed the unique rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories exterior of Larger China (which incorporates Mainland China, Hong Kong, Macao and Taiwan).
To this point, three indications for sac-TMT have been authorised and marketed in China for: EGFR mutant-positive regionally superior or metastatic non-squamous NSCLC following development on EGFR-TKI remedy and platinum-based chemotherapy; Unresectable regionally superior or metastatic TNBC who’ve acquired at the least two prior systemic therapies (at the least considered one of them for superior or metastatic setting); EGFR mutant-positive regionally superior or metastatic non-squamous NSCLC who progressed after remedy with EGFR-TKI remedy. The primary two indications listed above have been included in China’s Nationwide Reimbursement Drug Record (NRDL). This inclusion is predicted to carry medical advantages to a higher variety of most cancers sufferers.
Sac-TMT is the world’s first TROP2 ADC drug authorised for advertising and marketing in lung most cancers. As well as, the sNDA for sac-TMT for second-line and above remedy of HR+/HER2- BC was accepted by the Middle for Drug Analysis of the Nationwide Medical Merchandise Administration, and was included within the precedence evaluation and approval course of.
As of right this moment, Kelun-Biotech has initiated 9 registrational medical research in China. MSD has initiated 15 ongoing Section 3 international medical research of sac-TMT as a monotherapy or with pembrolizumab or different anti-cancer brokers for a number of varieties of most cancers. These research are sponsored and led by MSD.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and international collaboration of revolutionary organic medication and small molecule medication. Kelun-Biotech focuses on main illness areas akin to strong tumors, autoimmune, inflammatory, and metabolic ailments, and in establishing a globalized drug improvement and industrialization platform to deal with the unmet medical wants in China and the remainder of world. Kelun-Biotech is dedicated to turning into a number one international enterprise within the area of revolutionary medication. At current, Kelun-Biotech has greater than 30 ongoing key revolutionary drug tasks, of which 4 tasks have been authorised for advertising and marketing, 1 undertaking is within the NDA stage and greater than 10 tasks are within the medical stage. Kelun-Biotech has established one of many world’s main proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC tasks authorised for advertising and marketing, and a number of ADC and novel DC property in medical or preclinical analysis stage. For extra data, please go to https://en.kelun-biotech.com/.
[1] KEYTRUDA® (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. |
